Nanjing King-Friend Biochemical Pharma (NKF) invested $95 million in Meitheal Pharma of Chicago, a generic injectables company, raising its holdings to a majority stake. Meithall distributes NKF products in the US. Founded in 2017, Meitheal has 12 FDA-approved products for anti-infective, oncolytic and intensive care indications. In addition, it has 49 products in R&D, 24 products under review in the US, and eight products planned for 2019 launches. Nanjing King-Friend is known for its heparin-related products, though it has expanded into critical care and oncology. More details....
Stock Symbol: (SHA: 603707)
Share this with colleagues: